QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF For Our Patients Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Epstein, B. J Articles by Gums, J. G Search for Related Content PubMed PubMed Citation Articles by Epstein, B. J Articles by Gums, J. G

CARDIOLOGY

Angiotensin Receptor Blockers versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations

Postdoctoral Fellow, Departments of Pharmacy Practice and Community Health and Family Medicine, Colleges of Pharmacy and Medicine, University of Florida, Gainesville, FL

John G Gums, PharmD

Professor of Pharmacy and Medicine, Departments of Pharmacy Practice and Community Health and Family Medicine, Colleges of Pharmacy and Medicine, University of Florida

Reprints: Dr. Epstein, University of Florida, 625 SW 4th Ave., Gainesville, FL 32601-6430, fax 352/392-7766, epstein{at}chfm.ufl.edu

OBJECTIVE: To determine, through a review of the medical literature, whether there is adequate evidence to support the use of angiotensin receptor blockers (ARBs) in place of angiotensin-converting enzyme (ACE) inhibitors in high-risk populations, focusing on the prevention of death and myocardial infarction (MI).

DATA SOURCES: Original investigations, reviews, and meta-analyses were identified from the biomedical literature via a MEDLINE search (1966–August 2004). Published articles were also cross-referenced for pertinent citations, and recent meeting abstracts were searched for relevant data.

STUDY SELECTION AND DATA EXTRACTION: All articles identified during the search were evaluated. Preference was given to prospective, randomized, controlled trials that evaluated major cardiovascular endpoints and compared ARBs with ACE inhibitors, active controls, or placebo.

DATA SYNTHESIS: The renin–angiotensin system plays a pivotal role in the continuum of cardiovascular disease and represents a major therapeutic target in the treatment of patients at risk for vascular events. While ACE inhibitors have been definitively shown to prevent death and MI, studies with ARBs in similar populations have not reduced these endpoints. In clinical trials that enrolled patients with heart failure, post-MI, diabetes, and hypertension, ARBs did not prevent MI or prolong survival compared with ACE inhibitors, other antihypertensives, or placebo.

CONCLUSIONS: ACE inhibitors and ARBs should not be considered interchangeable, even among patients with a documented history of ACE inhibitor intolerance. ARBs can be considered a second-line alternative in such patients with the realization that they have not been shown to prevent MI or prolong survival.

Key Words: angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, cardiovascular disease, myocardial infarction

Published Online, February 8, 2005. www.theannals.com, DOI 10.1345/aph.1E478

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-05-008-H01

This article has been cited by other articles:

				M. L Johnson, L. A Petersen, R. Sundaravaradan, M. M Byrne, J. C Hasche, N. I Osemene, I. I Wei, and R. O Morgan The Association of Medicare Drug Coverage with Use of Evidence-Based Medications in the Veterans Health Administration Ann. Pharmacother., October 1, 2009; 43(10): 1565 - 1575. [Abstract] [Full Text] [PDF]

				M. H. Strauss and A. S. Hall Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox Circulation, August 22, 2006; 114(8): 838 - 854. [Full Text] [PDF]

				S. G. Tsouli, E. N. Liberopoulos, D. N. Kiortsis, D. P. Mikhailidis, and M. S. Elisaf Combined Treatment With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers: A Review of the Current Evidence Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 1 - 15. [Abstract] [PDF]